Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.
You may also be interested in...
Erbitux Label Update Includes Lengthened Observation For Infusion Reactions
Corresponding Bristol/ImClone “Dear Doctor” letter also describes new labeling language on severe electrolyte depletion observed in ongoing clinical trials of the colorectal cancer drug.
Erbitux Label Update Includes Lengthened Observation For Infusion Reactions
Corresponding Bristol/ImClone “Dear Doctor” letter also describes new labeling language on severe electrolyte depletion observed in ongoing clinical trials of the colorectal cancer drug.
ImClone/Bristol Seek Priority Review For Erbitux Head And Neck Cancer Indication
Erbitux sBLA filing for head and neck cancer follows independent confirmatory review of Phase III trial.